Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLEVER: CLadribine tablets - EValuation of therapy satisfaction - CLEVER

Next Previous
Search
Trial Profile

CLEVER: CLadribine tablets - EValuation of therapy satisfaction - CLEVER

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms CLEVER
  • Sponsors Merck Serono

    • Most Recent Events

    • 15 Oct 2021 Primary endpoint has been met. (The primary endpoint is overall treatment satisfaction with Cladribine tablets as assessed by the Global Satisfaction subscale score of the questionnaire TSQM-14 (Version 1.4) in week 24.),as per Results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 15 Oct 2021 Results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 01 May 2020 Results (n=67) presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top